epiplepsy
Takeda agree $856m deal with Ovid to take over soticlestat development
March 4, 2021Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat
Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
